Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice

Gene Ther. 2002 Oct;9(19):1271-7. doi: 10.1038/sj.gt.3301798.

Abstract

It has been previously shown that vascular endothelial growth factor (VEGF) plays a central role in promoting angiogenesis during wound repair and that healing-impaired diabetic mice show decreased VEGF expression levels. In order to investigate the potential benefits of gene therapy with growth factors on wound repair, a replication-deficient recombinant adenovirus vector carrying the human VEGF(165) gene (AdCMV.VEGF(165)) was topically applied on excisional wounds of streptozotocin-induced diabetic mice. Treatment with AdCMV.VEGF(165) significantly accelerated wound closure when compared with AdCMV.LacZ-treated, as well as saline-treated control mice, by promoting angiogenesis at the site of injury. Our findings suggest that AdCMV.VEGF(165) may be regarded as a therapeutic tool for the treatment of diabetic ulcers.

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Diabetes Mellitus, Experimental / physiopathology*
  • Endothelial Growth Factors / genetics
  • Endothelial Growth Factors / physiology*
  • Gene Transfer Techniques
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Granulation Tissue / anatomy & histology
  • Lymphokines / genetics
  • Lymphokines / physiology*
  • Male
  • Mice
  • Neovascularization, Physiologic / physiology*
  • Skin / blood supply
  • Skin / injuries*
  • Transduction, Genetic
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Wound Healing / physiology*

Substances

  • Endothelial Growth Factors
  • Lymphokines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors